Legislation enacted by Congress last year outlawing hemp-derived products containing cannabinoids "not capable of being naturally produced by cannabis" went into effect on Nov. 12.
Lawmakers included the provisions in a broader government funding bill last November. Other provisions in the bill call for a federal prohibition on the production, possession, and sale of any hemp-derived product containing naturally derived cannabinoids above 0.4 milligrams per container. However, in September lawmakers passed a stopgap funding bill delaying the implementation of the broader ban until Dec. 11.
Products containing novel synthetically produced cannabinoids such as THC-O and HHC are targeted by the new ban. Representatives from the US Drug Enforcement Administration argued that these products fell beyond the scope of the 2018 Farm Bill, although the federal courts had rejected their opinion.
It remains uncertain whether members of Congress will consider legislation in the coming weeks amending the forthcoming broader ban on hemp-derived products. This week, representatives of the Veterans of Foreign Wars sent a letter to Congressional leaders demanding a halt to the ban. If enacted, the ban would also likely disrupt a newly initiated Medicare/Medicaid pilot program providing eligible beneficiaries access to designated hemp products containing up to 3 mg of THC.
NORML has consistently urged federal officials to establish regulatory guidelines governing the production, testing, labeling, and marketing of hemp-derived cannabinoid products—most of which are unregulated and many of which are of variable quality and purity. (NORML)
Image of THC molecule via Boston Hempire







Recent comments
2 weeks 1 day ago
2 weeks 3 days ago
2 weeks 3 days ago
2 weeks 3 days ago
4 weeks 5 hours ago
20 weeks 2 days ago
20 weeks 5 days ago
28 weeks 6 days ago
30 weeks 7 hours ago
30 weeks 5 days ago